Abstract Views :186 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutics, RRKS College of Pharmacy, Bidar-585402, IN
2 Department of Pharmacology, RRKS College of Pharmacy, Bidar-585402, IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 7, No 1 (2015), Pagination: 44-50
Abstract
In the present study, Mouth dissolving tablets of Meloxicam were designed with a view to enhance patient compliance. Meloxicam, a new non-steroidal anti-inflammatory agent mainly used for the treatment of osteoarthritis and rheumatoid arthritis. However, it may cause gastro-intestinal tract disturbances/induce ulcer to avoid these complications we designed Mouth dissolving tablets of Meloxicam. The prepared batches of Mouth dissolving tablets were evaluated for hardness and friability, drug dispersion time, drug content uniformity, wetting time, water absorption ratio and in vitro dispersion time. Based on in vitro dispersion time (approximately 8-30 s), all formulations were tested for in vitro drug release pattern (in Phosphate buffer), Short-term stability (40°C/ 75% RH for 3 months) and drug-excipient interaction study (IR spectroscopy). Among all the formulations, the formulation prepared by 6% sodium starch glycolate was found to have minimum dispersion time (8.77 s) and Short-term stability studies on the promising formulation indicated that there were no significant changes in drug content and in vitro dispersion time.
Keywords
Mouth Dissolving Tablets (MDT), Novel Drug Delivery Systems (NDDS) Meloxicam, Sodium Starch Glycolate, Croscarmellose Sodium.
